Staphylococcus Aureus Infections - Pipeline Review, H1 2015 is now available at RnRMarketResearch store. This report provides comprehensive information on the therapeutic development for Staphylococcus Aureus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Staphylococcus Aureus Infections and special features on late-stage and discontinued projects. Get a copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=403544 . (This is a premium report price at US$2000 for a single user PDF license)
Some of the Company profiles mentioned in this report are AmpliPhi Biosciences Corporation, Bharat Biotech International Limited, Ildong Pharmaceutical Co., Ltd., iNtRON Biotechnology Inc., LegoChem Biosciences, MicuRx Pharmaceuticals, NanoBio Corporation, NovoBiotic Pharmaceuticals, Procarta Biosystems Ltd, Sumitomo Dainippon Pharma Co., Ltd., Wockhardt Limited, Yungjin Pharm Ind. Co., Ltd.
- The report reviews key players involved in the therapeutics development for Staphylococcus Aureus Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Staphylococcus Aureus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Staphylococcus Aureus Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline productsGlobal Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.